Moderna Experiences Significant Stock Selloff After Melanoma Vaccine Trial Data Release
What happened
Moderna's stock plummeted by 20-25% after the release of melanoma vaccine trial data that fell short of investor expectations.
The Context
- Trial Results: The Phase 3 trial showed a 42% reduction in recurrence risk when combined with immunotherapy, but investors anticipated more.
- Market Reaction: Following a significant stock rally in August, the selloff erased approximately $24 billion in market value, reflecting investor caution.
- Pipeline Scrutiny: With post-pandemic revenue challenges, Moderna's future relies heavily on its mRNA cancer vaccine pipeline, which is under increased scrutiny.
The Number
— This is the market value erased in a single-day selloff on October 22, 2026, underscoring the volatility and high stakes in biotech investments.
Takeaway
As Moderna navigates its pipeline challenges, expect continued volatility that could influence broader market trends in biotechnology.
Markets desk coverage, trading insights, and investor updates.
"WSJ’s markets reporting provides in-depth analysis and context for investors."
— A47 Editor
Moderna Investors Should Brace for More Whiplash
Moderna's stock has recently experienced significant volatility, with a sharp decline of up to 25% following the leak of trial data for its personalized mRNA cancer vaccine. This data, which was expected to be presented at an upcoming conference, fai...
Public health, medical research, healthcare policy, and pharmaceutical developments.
"Dow Jones is a major financial news provider with a professional tone and broad coverage, including specialized health-sector reporting."
— A47 Editor
Heard on the Street: Moderna’s cancer vaccine passed its first big test this past week. The bigger problem is that its stock is priced as if it has already passed them all.
Moderna's cancer vaccine recently passed its first significant test, yet the company's stock price reflects expectations of far greater success than currently demonstrated. Despite this initial positive outcome, the stock has faced volatility, indica...
Editor-curated FT homepage stories spanning markets, business, world, and opinion.
"The Financial Times is a globally respected business publication with a centrist/center-left tone and strong markets focus."
— A47 Editor
Moderna shares sink after leaked cancer data missed expectations
Moderna's shares experienced a significant decline after the company announced that its melanoma vaccine treatment, which reduced the risk of recurrence or death by 58%, did not meet Wall Street's high expectations. This news led to a drop in investo...
Stock market news, investing ideas, and trading analysis.
"TheStreet provides market news and retail-investor-focused analysis."
— A47 Editor
Moderna stock’s 17% slump was a ‘sell the news’ event, analyst says
Moderna's stock experienced a significant 17% decline following the leak of trial data for its personalized mRNA cancer vaccine, developed in collaboration with Merck, which showed promising results but failed to meet Wall Street's high expectations.